New hope for sarcoma: Nano-Chemo combo targets tough tumors
NCT ID NCT07359053
First seen Jan 25, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This phase 2 study tests a new combination of drugs for people with advanced bone or soft tissue sarcomas that have worsened after standard treatment. The combo includes a nano-form of paclitaxel (to reduce side effects), gemcitabine, and a targeted therapy chosen by tumor type. The goal is to see if this approach can shrink tumors and control the disease better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Sixth Peolple'S Hospital
RECRUITINGShanghai, CH, 200233, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel polymer micelles, gemcitabine, lenvatinib, anlotinib
What this could lead to
If successful, this could offer a more effective and safer treatment option for people with advanced sarcomas who have run out of standard options.
What could go wrong
This is an early-phase, small study (46 people) with no control group, so results may not be definitive. The drug combination may cause significant side effects like fatigue, high blood pressure, or low blood cell counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.